MARKET

ISR

ISR

Isoray
AMEX

Real-time Quotes | Nasdaq Last Sale

0.2970
+0.0060
+2.06%
After Hours: 0.3000 +0.003 +1.01% 18:44 07/05 EDT
OPEN
0.2940
PREV CLOSE
0.2910
HIGH
0.3090
LOW
0.2841
VOLUME
178.05K
TURNOVER
0
52 WEEK HIGH
0.7900
52 WEEK LOW
0.2521
MARKET CAP
42.19M
P/E (TTM)
-6.7347
1D
5D
1M
3M
1Y
5Y
Isoray's Cesium-131 Featured in Presentations at American Brachytherapy Society's Annual Conference
The growing body of information regarding Isoray, Inc.'s (NYSE:ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society's annual
Benzinga · 06/21 12:13
Isoray To Host Lunch Symposium At American Brachytherapy Society’s Annual Conference
RICHLAND, Wash., June 15, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a lunch symposium featuring Dr. Stephen J. Frank of the MD Anderson Ca...
GlobeNewswire · 06/15 12:10
IsoRay (ISR) Reports Q3 Loss, Lags Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of 0% and 7.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 22:25
IsoRay GAAP EPS of -$0.01 in-line, revenue of $2.91M misses by $0.09M
IsoRay press release (NYSE:ISR): Q3 GAAP EPS of -$0.01 in-line. Revenue of $2.91M (+11.9% Y/Y) misses by $0.09M. Shares +3%.
Seekingalpha · 05/10 20:48
IsoRay Q3 EPS $(0.01), Same YoY, Sales $2.91M Miss $3.11M Estimate
IsoRay (AMEX:ISR) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported quarterly sales of $2.91 million which missed the analyst consensus estimate of
Benzinga · 05/10 20:23
-- Earnings Flash (ISR) ISORAY Posts Q3 Loss $-0.01, vs. Street Est of $-0.01
MT Newswires · 05/10 16:34
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -5.26% and 6.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 21:55
Isoray to Participate in the Oppenheimer 32nd Annual Healthcare Conference
RICHLAND, Wash., March 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy, today announced that Chief Executive Officer Lori Woods will participate in a virtual fireside chat at ...
GlobeNewswire · 03/10 13:13
More
No Data
Learn about the latest financial forecast of ISR. Analyze the recent business situations of Isoray through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
33.33%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ISR stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
High1.000
Average1.000
Low1.000
Current 0.2970
EPS
Actual
Estimate
-0.02-0.01-0.01-0.00
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 29
Institutional Holdings: 3.97M
% Owned: 2.79%
Shares Outstanding: 142.04M
TypeInstitutionsShares
Increased
3
180.54K
New
3
75.96K
Decreased
3
935.88K
Sold Out
6
261.51K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.16%
Healthcare Equipment & Supplies
-0.07%
Key Executives
Non-Executive Chairman/Independent Director
Michael Mccormick
Chief Executive Officer/Director
Lori Woods
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance/Controller/Secretary
Mark Austin
Chief Financial Officer
Jonathan Hunt
Chief Operating Officer/Vice President/Director of Human Resources
Jennifer Streeter
Other
William Cavanagh
Independent Director
Alan Hoffmann
Independent Director
Philip Vitale
No Data
No Data
About ISR
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Cesium-131 seed is classified as a Class II device.

Webull offers kinds of IsoRay, Inc. stock information, including AMEX:ISR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ISR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ISR stock methods without spending real money on the virtual paper trading platform.